DF Dent & Co. Inc. Sells 27,041 Shares of Repligen Co. (NASDAQ:RGEN)

DF Dent & Co. Inc. reduced its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 4.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 563,280 shares of the biotechnology company's stock after selling 27,041 shares during the quarter. DF Dent & Co. Inc. owned 1.01% of Repligen worth $81,079,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Signaturefd LLC raised its stake in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new position in Repligen during the 4th quarter valued at about $29,000. Resources Management Corp CT ADV bought a new stake in shares of Repligen in the third quarter worth approximately $37,000. Quarry LP raised its holdings in shares of Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 239 shares during the last quarter. Finally, UMB Bank n.a. lifted its position in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 110 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax purchased 250 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.20% of the company's stock.

Repligen Price Performance

RGEN stock traded down $1.02 during trading on Tuesday, reaching $115.09. The company's stock had a trading volume of 232,636 shares, compared to its average volume of 689,087. The company's fifty day moving average is $148.99 and its 200-day moving average is $147.41. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The company has a market capitalization of $6.46 billion, a P/E ratio of -226.02, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. On average, research analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RGEN has been the subject of a number of research reports. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. HC Wainwright reissued a "buy" rating and issued a $180.00 target price on shares of Repligen in a report on Friday, February 21st. Royal Bank of Canada increased their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday, February 21st. TD Cowen started coverage on shares of Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 target price for the company. Finally, StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research report on Friday. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Repligen has a consensus rating of "Moderate Buy" and a consensus price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.